Cargando…

Genetic Modification of T Cells for the Immunotherapy of Cancer

Immunotherapy is a beneficial treatment approach for multiple cancers, however, current therapies are effective only in a small subset of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy where T cells targeting the tumor cells are transferred to the patient with several primary for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quinn, Suzanne, Lenart, Natasha, Dronzek, Victoria, Scurti, Gina M., Hossain, Nasheed M., Nishimura, Michael I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949949/ https://www.ncbi.nlm.nih.gov/pubmed/35335089 http://dx.doi.org/10.3390/vaccines10030457

Ejemplares similares

Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
por: Wang, Siao-Yi, et al.
Publicado: (2021)

Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
por: Regan, Courtney, et al.
Publicado: (2013)

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
por: Islam, Rasa, et al.
Publicado: (2021)

New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy
por: Oberholtzer, Nathaniel, et al.
Publicado: (2022)

Treating Acquired Factor VIII Inhibitor and Tumor-Induced Hypoglycemia in a Case of Relapsed Diffuse Large B-Cell Lymphoma
por: Baker, Preston, et al.
Publicado: (2023)

Genetically engineered T cells for cancer immunotherapy
por: Li, Dan, et al.
Publicado: (2019)

Genetic Modification of T Cells
por: Morgan, Richard A., et al.
Publicado: (2016)

Targeting the RNA m(6)A modification for cancer immunotherapy
por: Li, Xinxin, et al.
Publicado: (2022)

Immunotherapy in Anal Cancer
por: Dhawan, Natasha, et al.
Publicado: (2023)

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy
por: Cheng, Qinzhen, et al.
Publicado: (2023)

Possible Biomarkers for Cancer Immunotherapy
por: Otoshi, Takehiro, et al.
Publicado: (2019)

Metabolic Modifications, Inflammation, and Cancer Immunotherapy
por: Zheng, Sihao, et al.
Publicado: (2021)

The prospect of genetically engineering natural killer cells for cancer immunotherapy
por: Poon, Angie Yu Ching, et al.
Publicado: (2022)

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer
por: Walker, Suzanne
Publicado: (2016)

Transgenic T-cell receptor immunotherapy for cancer: building on clinical success
por: Oppermans, Natasha, et al.
Publicado: (2020)

Biological roles of RNA m(5)C modification and its implications in Cancer immunotherapy
por: Song, Hang, et al.
Publicado: (2022)

Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
por: Suraya, Ratoe, et al.
Publicado: (2022)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)

The importance of N6-methyladenosine modification in tumor immunity and immunotherapy
por: Zhang, Ze, et al.
Publicado: (2022)

Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020)

Innovative approaches to immunotherapy in breast cancer
por: Quinn, Kylie M.
Publicado: (2020)

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
por: Ansary, Tuba M., et al.
Publicado: (2022)

Immunotherapy in inoperable stage III non-small cell lung cancer: a review
por: Jain, Natasha A, et al.
Publicado: (2019)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Advances in post-translational modifications of proteins and cancer immunotherapy
por: Li, Yanqing, et al.
Publicado: (2023)

Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control
por: Kesarwani, Pravin, et al.
Publicado: (2016)

Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
por: Sun, Wanyu, et al.
Publicado: (2018)

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
por: Mehrotra, Shikhar, et al.
Publicado: (2017)

The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy
por: Routy, Jean-Pierre, et al.
Publicado: (2016)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
por: Ye, Baixin, et al.
Publicado: (2017)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
por: Rini, Brian I., et al.
Publicado: (2016)

Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy
por: Aldahlawi, Alia M., et al.
Publicado: (2021)

Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
por: Hossain, Sultana Mehbuba, et al.
Publicado: (2023)

The emerging role of γδ T cells in cancer immunotherapy
por: Nussbaumer, Oliver, et al.
Publicado: (2019)

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
por: Dai, Weijing, et al.
Publicado: (2022)

Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy
por: Dai, Xiangpeng, et al.
Publicado: (2022)

Delivery technologies for T cell gene editing: Applications in cancer immunotherapy
por: Atsavapranee, Ella S., et al.
Publicado: (2021)

γδ T cells in cancer immunotherapy
por: Zou, Chang, et al.
Publicado: (2016)

T-cell agonists in cancer immunotherapy
por: Choi, Yeonjoo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_esu3rdea1k1va3gvhk6r4c81f6